BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Home > article

Medytox acquires 16.7% stake in Daewoong's U.S. partner for ending legal battle

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : Febuary 22, 2021, 11:00 | Updated : Febuary 22, 2021, 11:00
  • 트위터
  • 페이스북
  • 웨이보
 

[Courtesy of Medytox]


SEOUL -- Medytox, a major botulinum toxin (botox) producer in South Korea, has acquired a 16.7 percent stake in Evolus, the U.S. partner of Daewoong Pharmaceutical, as part of a deal to end a protracted legal battle and rescind a U.S. trade panel's decision in December 2020 to order a 21-month ban on Daewoong's products in the American market.

Medytox said in a regulatory filing on February 22 that the company and its U.S. partner, AbbVie, purchased a 16.7 percent stake in Evolus for 53.5 billion won ($48.5 million). Through the deal, Medytox got leeway to make up for losses. It's Medytox that has launched a legal fight, but the company suffered a setback in the domestic market in June 2020 when South Korea's public health watchdog canceled approval for three botox products for fabricating test data.

Evolus agreed to pay $35 million in cash, plus royalties on botox sales in the U.S. for 21 months. It was also given a license to sell botox in the European Union and other countries. Medytox and its American partner would ask the International Trade Commission (ITC) to rescind its import ban. However, Daewoong is not a party to the agreement, which would not affect disputes in South Korea and elsewhere.

Botulism toxins are produced by bacteria of the genus Clostridium. Medytox introduced its botox product, named Meditoxin in South Korea and Neuronox abroad, for the aesthetic treatment of facial wrinkles. Daewoong unveiled Nabota for the treatment of frown lines in 2016 and secured approval from the U.S. Food and Drug Administration.

Medytox has filed lawsuits in U.S. and South Korean courts, accusing Daewoong of violating trade secrets by recruiting a former Medytox employee to steal information on strains and manufacturing. Medytox insisted that its botulinum strain "Meditoxin" cannot be found in a natural state because it does not form spores. Daewoong said that Medytox's botulinum strain is not a trade secret as its manufacturing process has already been published in papers.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Daewoong shares up in domestic market after 21-month ban by U.S. trade panel  .
    Daewoong shares up in domestic market after 21-month ban by …
  • .Daewoong agrees to sell therapeutic botox product through U.S. partner.
    Daewoong agrees to sell therapeutic botox product through U.…
  • .Daewoong allowed to sell botox product in Indonesia, UAE .
    Daewoong allowed to sell botox product in Indonesia, UAE
  • .Meditox ordered to recall some botox products distributed abroad  .
    Meditox ordered to recall some botox products distributed ab…

Real Time Photo News

  • .KT jumps into Vietnams music streaming market with digital platform.

    KT jumps into Vietnam's music streaming market with digital platform

  • .K-pop girl band MAMAMOOs label acquires rival entertainment company.

    K-pop girl band MAMAMOO's label acquires rival entertainment company

  • .BTS agency expands U.S. business scope thru acquisition of Ithaca Holdings.

    BTS agency expands U.S. business scope thru acquisition of Ithaca Holdings

  • .CJs drama-making wing forges partnership with webcomics studio YLAB.

    CJ's drama-making wing forges partnership with webcomics studio YLAB

  • .Historical inaccuracies lead to rare withdrawal of TV series in S. Korea.

    Historical inaccuracies lead to rare withdrawal of TV series in S. Korea

Latest News

more+

  • [FOCUS] President Moon hails rollout of home-made fighter jet as 'historic milestone'
  • Researchers develop tiny wearable metasurface gas sensor for holographic visual alarms
  • Researchers discover method to mass-produce carminic acid from glucose
  • KT jumps into Vietnam's music streaming market with digital platform
  • Daewoo shipyard gets smarter with advanced digital technologies
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view